|
2024 Clinical Endocrinology Update and Endocrine Board Review Meeting
Date(s):
September 6 21, 2024
Venue:Virtual Meeting
Your Location Online Access
Website:Not available
Fee(s):This event has a fee
Description:Endocrine Board Review Online September 6-8, 2024
Clinical Endocrinology Update Online September 19-21, 2024 ...
|
-
CEU 2024 Online
Type: Clinical Endocrinology Update
Clinical Endocrinology Update (CEU) is a comprehensive three-day online meeting for physicians and researchers to learn about critical issues and the latest advances in endocrinology. The sessions will be organized around nine core topics: Adrenal, Calcium & Bone, Diabetes Mellitus, Pituitary, Obesity & Lipids, Female Reproduction, Male Reproduction, Transgender Care, and Thyroid. Your registrati...
-
3:15PM - 4:15PM
Evaluating Advanced Technology for Patient-Specific Management of Type 1 Diabetes
Type: Ancillary Symposia (Complimentary)
About 1.9 million people in the U.S. have type 1 diabetes mellitus (T1DM), a chronic autoimmune condition that increases the risk of serious complications and affects quality of life. New technologies can improve glycemic control for patients requiring multiple insulin injections daily, but healthcare providers (HCPs) often struggle to create personalized treatment plans using these devices....
-
2:00PM - 3:00PM
Menopause Science and Clinical Care
Type: Ancillary Symposia (Complimentary)
Menopause, a natural part of aging marking the end of menstrual cycles, presents diverse patient experiences and delays in diagnosis. While various hormonal and nonhormonal therapies exist, many patients seek optimized treatment plans tailored to their symptom severity....
-
3:15PM - 4:15PM
Patient POV: Shared Decision Making in the Management of T2DM with Cormorbidities
Type: Ancillary Symposia (Complimentary)
Type 2 diabetes mellitus (T2DM) management is complex and requires regular checkups, self-monitoring of blood glucose, dietary and lifestyle changes, and pharmacologic treatments to improve glycemic control and prevent comorbidities. For patients at high risk for atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD), treatment guidelines recommend age...
|
|
Track information is not available at this time.
|
|
Speaker information is not available at this time.
|
|
Sponsor information is not available at this time.
|
|
|
|